Will US Clinical Study Diversity Guidance Cloud Chinese Firms’ Prospects For Going Global?

 
• By Brian Yang

The latest FDA guidance will have profound impact to Chinese biotech sector at a time when going global and a US approval is vital to its very survival.

Chinese flag
US FDA clinical study diversity guidance could cloudy Chinese biotech's going global prospect • Source: Shutterstocks

More from Diversity & Inclusion

More from Clinical Trials